J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Resignation of Director
Resignation of Director12-03-2022
12-03-2022
J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Earnings conference call Transcript and Audio recording18-02-2022
Earnings Call for Q3FY22 of J B Chemicals & Pharmaceuticals
Conference Call with J B Chemicals & Pharmaceuticals Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.15-02-2022
J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting of extract of consolidated financial results for quarter ended on December 31, 202115-02-2022
J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Board Meeting Outcome for Declaration Of Interim Dividend Of Rs. 8.50 Per Share Of FV Rs. 2 (425%) For FY 2021-2022
Outcome of meeting of Board of Directors-Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 read with circular CIR/CFD/CMD/4/2015 dated September 9, 2015- Declaration of interim dividend of Rs. 8.50 per share of FV Rs. 2 (425%) for FY 2021-202214-02-2022
J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Outcome Of Meeting Of Board Of Directors - Unaudited Financial Results For The Quarter Ended December 31, 2021
Outcome of meeting of Board of Directors - Unaudited Financial Results for the quarter ended December 31, 202114-02-2022
J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investors/analysts call with management08-02-2022
J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended December 31, 2021; And (Ii) Declaration Of Interim Dividend, If Any, For The Financial Year 2021-22
J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 ,inter alia, to consider and approve (i) unaudited financial results for the quarter ended December 31, 2021; and (ii) declaration of Interim dividend, if any, for the financial year 2021-2207-02-2022